IFM Therapeutics, LLC, a biopharma focused on developing therapies that modulate novel targets in the innate immune system, has launched IFM Due (pronounced du-way), a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that aim to block excessive production of interferon and other pro-inflammatory cytokines via the cGAS/STING pathway, which is known to drive a range of serious diseases. The company also announced that award-winning immunologist Andrea Ablasser of the ...